Search
for

    Research 3 of 28

    1. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea Frontiers in Endocrinology · 2019 · 39 citations
    2. Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies Biomedicines · 2025
    3. PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands Journal of Experimental & Clinical Cancer Research · 2025 · 7 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →